Virtus Biotech Clinical Trials ETF
16 hedge funds and large institutions have $6.15M invested in Virtus Biotech Clinical Trials ETF in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
45% more funds holding
Funds holding: 11 → 16 (+5)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
29% less capital invested
Capital invested by funds: $8.61M → $6.15M (-$2.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$913K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$776K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$426K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$94.7K |
| 5 |
Morgan Stanley
New York
|
+$44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$1.33M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$565K |
| 3 |
LPL Financial
San Diego,
California
|
-$365K |
| 4 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
-$254K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$26.4K |
BBC Hedge Fund Activity: Q3 2015 in Review
16 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2015, worth a combined $6.15M — down 29% from $8.61M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BBC positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Credit Suisse, adding an estimated $913K. The largest seller was Jane Street, cutting an estimated $1.33M.
- 16 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2015, up from 11 in Q2 2015.
- Funds reported $6.15M of Virtus Biotech Clinical Trials ETF stock for Q3 2015, down 29% quarter-over-quarter.
- 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2015 and 1 closed out, a net change of +5 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2015 was Credit Suisse, an estimated $913K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2015 was Jane Street, an estimated $1.33M sold.
Based on aggregated 13F filings for Q3 2015.